OBJECTIVE:To observe clinical efficacy of Shenshao capsules in the treatment of unstable angina(UA)of coro-nary heart disease,and its effects on heart rate,blood pressure,myocardial consumption of oxygen (MCO),serum levels of hs-CRP and MMP-9. METHODS:77 UA patients with coronary heart disease selected from our hospital during May 2014-May 2016 were divided into observation group (39 cases) and control group (38 cases) according to random number tablet. Control group received rountine treatment. Observation group was additionally given Shenshao capsule 1.2 g,tid,on the basis of control group. Both groups were treated for 4 weeks. The heart rate,blood pressure,myocardial oxygen consumption,serum levels of hs-CRP and MMP-9 in 2 groups were observed before and after treatment;stopping and reduced rate of nitroglycerin,and therapeu-tic efficacy of ECG ST segment were compared between 2 groups. RESULTS:There was no statistical significance in heart rate, blood pressure,myocardial oxygen consumption,serum levels of hs-CRP and MMP-9 between 2 groups before treatment (P>0.05). After treatment,above indexes of 2 groups were decreased significantly,and the observation group was significantly lower than the control group,with statistical significance (P<0.05). The stopping and reduced rate of nitroglycerin,total response rate of ECG ST segment were 82.1%,87.2%in observation group,which were better than 63.2%,78.9%in control group,with statis-tical significance(P<0.05). CONCLUSIONS:Shenshao capsules is effective for coronary heart disease UA,and can effectively re-duce heart rate,blood pressure,myocardial oxygen consumption,serum levels of hs-CRP and MMP-9.

Objective:To evaluate the inhibitory effect of Herceptin on HeLa,SiHa cells and to investigate the synergistic mechanism of Herceptin and Carboplatin.Methods:HeLa and SiHa cells were treated with Herceptin(at 5,10,20,40,and 80 ?g/ml),Carboplatin(at 0.5,1,2,4,and 8 ?g/ml),and Her+CBP[(10+1),(20+2),and(40+4)?g/ml] separately.The untreated cells were taken as control.SP immunohistochemical method was used to detect the protein expression of HER-2/neu and downstream Ras oncogene.MTT method was used to study the inhibition effect of Herceptin on HeLa,SiHa cells and its synergetic effect with carboplatin.FCM was used to detect the cell apoptosis and cell cycle.The mRNA expression of her-2/neu and ras were assessed by RT-PCR;the protein expression of HER-2/neu and Ras were studied by Western blotting.Results:Herceptin significantly inhibited cervical cancer cells proliferation,and there was a synergistic effect when combined with carboplatin(P

Background and objective As the prevalence of tobacco and the aging of the population, the incidence of lung cancer in the elderly rises. However, few elderly patients (older than 70 years old) with lung squamous cell carcinoma were involved into the clinical trials, which offered insuffcient clinical evidence for these patients. Lung squamous cell carcino-ma patients older than 80 years old were included in our study to analyze the clinical characteristics, treatment and prognostic factors, and to explore the optimal treatment choices for these patients.Methods We retrospectively analyzed the clinical fea-tures of 38 elderly patients with lung squamous carcinoma and summarized the treatment under the clear diagnosis and clini-cal staging.Results Elderly patients with squamous cell carcinoma can choose surgery, radiotherapy and chemotherapy based on diagnosis and clinical staging when their physical condition is permitted.Conclusion Because of the short life expectancy of patients more than 80 years old, fewer of them could receive completed and effective treatment, comparing with patients between 70 and 80 years old.

Background and objectiveSmall cell lung cancer combined with squamous cell carcinoma are rare. hTe aim of this study was to analyze the clinicopathological characteristics and treatment, and explored the prognostic factors of this disease.MethodsBetween January 2004 and December 2012, 58 patients with cytopathologically conifrmed small cell lung cancers combined with squamous cell carcinoma were retrospectively analyzed.Kaplan-Meier methods were used to calculate the survival rate, andLog-rank test was used to examine differences between arms. hTeCox regression model was used to analyze the independent factors affecting the overall survival (OS).Results hTe OS of the 58 patients was 22.7 months with a range of 0.3 to 124.3 months. In univariate analysis, Karnofsky performance score before treatment, extensive disease, tumor stage were the considered prognostic factors affecting the OS rate (P<0.05).Cox multivariate analysis showed that only the tumor-node-metastasis (TNM) stage was the independent prognostic factor (P=0.019). hTe majority of the patients received multimodality therapy and chemotherapy was the main treatment. Distant metastasis was the main reasonfor the treatment failure.ConclusionCombined therapy with chemotherapy as the main treatment should be adopted in therapeutic regimen of the patients with small cell lung cancers combined with squamous cell carcinoma. TNM stage was the independent prognos-tic factor inlfuencing the OS.

Background and objective Squamous cell carcinoma (SCC) is a common pathological type of non-small cell lung cancer, and advanced lung SCC is incurable. Chemotherapy combined with anti-angiogenesis agents can pro-long the patients’ survival time. hTe aim of the study was to analyze the effcacy and safety of recombinant human endostatin (Endostar) in treating advanced lung SCC.Methods We retrospectively analyzed the short-term efficacy and toxicity of recombinant human endostatin combined with traditional chemotherapy regimens in treating 15 advanced lung squamous cell carcinoma patients in Department of Medical Oncology retrospectively, Cancer Hospital, Chinese Academy of Medical Sciences from November 2011 to May 2015. Treatment-related survival was also analyzed.Results Among the evaluble 14 patients, the best overall response was partial response in 5 patients (35.7%), stable disease in 7 patients (50.0%), and progres-sive disease in 2 patients (14.3%). hTe objective response rate (ORR) was 35.7%, and disease control rate (DCR) was 85.7%. hTe median progression-free survival (PFS) was 9.3 months. hTe main grade 3 toxicity was neutropenia (2/15, 13.3%) and vomitting (1/15, 6.7%).Conclusion Chemotherapy combined with recombinant human endostatin enabled good objective response in advanced SCC patients and had well security.

Lung cancer is the deadliest cancer in the worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% of lung tumor diagnoses. Squamous cell lung cancer (SQCLC) is a common pathological type, almost 20%-30% of NSCLC. Surgery, chemotherapy, and molecular targeted therapies are the mainstay of treatment for patients with SQCLC. But most patients are diagnosed at advanced stage so that they miss the chance of operation. While noteworthy outcomes have im-proved with adenocarcinoma of lung with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), a thera-peutic plateau for advanced squamous cell lung cancer patients are still not solved. EGFR-TKIs are unsuitable for or mostly in-effective in advanced SQCLC. Patients with advanced SQCLC ramain treated with platinum based chemotherapy. hTis reciew systematicly describe the treatment of squamous cell carcinoma of the lung.

Objective To observe the safety and short?term efficacy of sigle drug albumin?bound paclitaxel (ABP) in the treatment of elderly patients with advanced non?small cell lung cancer (NSCLC). Methods A total of 23 elderly patients with advanced NSCLC who received weekly ABP regimen (130 mg/m2/week) in our hospital from October 2011 to March 2014 were retrospectively evaluated. The short?term efficacy, progression?free survival ( PFS) , and overall survival ( OS) were analyzed. Results The median treatment period was 4 cycles (2?10 cycles). Partial response, stable disease, progressive disease, overall response rate, and disease control rate were 26.1%, 43.5%, 30.4%, 26.1% and 69.6%, respectively. The median PFS was 5.33 months (95% CI:2.95?7.70 months), while the median OS was 40.33 months (95% CI:29.82?50.83 months). Major adverse events included leucopenia (82.6%), neutropenia (78.3%), nausea or vomiting (56.5%), fatigue (52.2%), peripheral neuropathy (26.1%), myalgia/arthralgia (30.4%), thrombocytopenia ( 13. 0%) and arrhythmia ( 4. 3%) . The patients accompanied with chronic diseases had significantly higher incidence rate of peripheral neuropathy and myalgia/arthralgia compared with the patients without accompanied chronic diseases ( 50. 0% vs. 9. 1% and 66. 7% vs. 9. 1%, P<0. 05 for both ) . Conclusion The weekly single drug ABP regimen is effective and well?tolerated in elderly patients with advanced NSCLC.

Objective To observe the safety and short?term efficacy of sigle drug albumin?bound paclitaxel (ABP) in the treatment of elderly patients with advanced non?small cell lung cancer (NSCLC). Methods A total of 23 elderly patients with advanced NSCLC who received weekly ABP regimen (130 mg/m2/week) in our hospital from October 2011 to March 2014 were retrospectively evaluated. The short?term efficacy, progression?free survival ( PFS) , and overall survival ( OS) were analyzed. Results The median treatment period was 4 cycles (2?10 cycles). Partial response, stable disease, progressive disease, overall response rate, and disease control rate were 26.1%, 43.5%, 30.4%, 26.1% and 69.6%, respectively. The median PFS was 5.33 months (95% CI:2.95?7.70 months), while the median OS was 40.33 months (95% CI:29.82?50.83 months). Major adverse events included leucopenia (82.6%), neutropenia (78.3%), nausea or vomiting (56.5%), fatigue (52.2%), peripheral neuropathy (26.1%), myalgia/arthralgia (30.4%), thrombocytopenia ( 13. 0%) and arrhythmia ( 4. 3%) . The patients accompanied with chronic diseases had significantly higher incidence rate of peripheral neuropathy and myalgia/arthralgia compared with the patients without accompanied chronic diseases ( 50. 0% vs. 9. 1% and 66. 7% vs. 9. 1%, P<0. 05 for both ) . Conclusion The weekly single drug ABP regimen is effective and well?tolerated in elderly patients with advanced NSCLC.

Background and objective Epidermal growth factor receptor tyrosine kinase inhinitors (EGFR-TKIs) inhibit tumor growth by affecting signal transduction, and are well tolerated. hTe aims of this study was to observe the effect of erlotinib in patients with squamous cell lung cancer.Methods hTe 34 patients with squamous cell lung cancer treated with er-lotinib 150 mg orally once daily until disease progression or intolerable adverse reactions.Results hTe 7 patients were treated with erlotinib as ifrst-line treatment, 6 patients as maintenance therapy (1 case withdrawal of severe toxicity), 9 patients second-line treatment, 5 patients as third-line and 7 patients as further-line therapy. 11 patients died. hTe median progression-free sur-vival (PFS) was 3.5 months, ranging from 1 month to 55 months (the patient withdrawal of severe toxicity was not included). Conclusion Erlotinib was effective for patients with squamous cell lung cancer who can not tolerate chemotherapy or refused chemotherapy and with unknown EGFR status. Adverse reactions were tolerable.

Background and objective Advanced non-small cell lung cancer (NSCLC) is a common malignancy that is incurable. No standard treatment exists for recurrent patients. hTis article analyzed the effcacy and safety of sunitinib (37.5 mg qd) on a continuous daily dosing (CDD) schedule in treating recurrent advanced NSCLC. Methods We retrospec-tively analyzed the short-term effcacy and toxicity of sunitinib CDD in treating 17 patients who had previously undergone multiple cycles of therapy for advanced NSCLC in our hospital from January 2011 to December 2012. Treatment-related survival was also analyzed. Results Among the 17 patients, the best overall response was partial response in 1 patient (5.9%), stable disease in 7 patients (41.2%), and progressive disease in 9 patients (52.9%). hTe overall response rate was 5.9%, and the disease control rate was 47.1%. hTe median progression-free survival was 4.4 months (95%CI:4.05-7.46). hTe main grade 3/4 toxicity was hand-foot skin reaction. Conclusion Sunitinib (37.5 mg QD) CDD enabled good objective response in advanced NSCLC patients who had previously received multiple cycles of treatment and was well tolerated.